DMKPQ has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
DMKPQ has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today (2024-05-15), DMK Pharmaceuticals's current share price is $0.03145. DMK Pharmaceuticals's Cyclically Adjusted Revenue per Share for the quarter that ended in Sep. 2023 was $21.02. DMK Pharmaceuticals's Cyclically Adjusted PS Ratio for today is 0.00.
The historical rank and industry rank for DMK Pharmaceuticals's Cyclically Adjusted PS Ratio or its related term are showing as below:
During the past years, DMK Pharmaceuticals's highest Cyclically Adjusted PS Ratio was 16.13. The lowest was 0.02. And the median was 2.49.
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.
DMK Pharmaceuticals's adjusted revenue per share data for the three months ended in Sep. 2023 was $0.001. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $21.02 for the trailing ten years ended in Sep. 2023.
The historical data trend for DMK Pharmaceuticals's Cyclically Adjusted PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DMK Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | |
Cyclically Adjusted PS Ratio | Get a 7-Day Free Trial | 0.60 | 0.53 | 0.37 | 0.11 | 0.03 |
For the Drug Manufacturers - Specialty & Generic subindustry, DMK Pharmaceuticals's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Drug Manufacturers industry and Healthcare sector, DMK Pharmaceuticals's Cyclically Adjusted PS Ratio distribution charts can be found below:
* The bar in red indicates where DMK Pharmaceuticals's Cyclically Adjusted PS Ratio falls into.
Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.
DMK Pharmaceuticals's Cyclically Adjusted PS Ratio for today is calculated as
Cyclically Adjusted PS Ratio | = | Share Price | / | Cyclically Adjusted Revenue per Share |
= | 0.03145 | / | 21.02 | |
= | 0.00 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DMK Pharmaceuticals's Cyclically Adjusted Revenue per Share for the quarter that ended in Sep. 2023 is calculated as:
For example, DMK Pharmaceuticals's adjusted Revenue per Share data for the three months ended in Sep. 2023 was:
Adj_RevenuePerShare | = | Revenue per Share | / | CPI of Sep. 2023 (Change) | * | Current CPI (Sep. 2023) |
= | 0.001 | / | 129.8595 | * | 129.8595 | |
= | 0.001 |
Current CPI (Sep. 2023) = 129.8595.
DMK Pharmaceuticals Quarterly Data
Revenue per Share | CPI | Adj_RevenuePerShare | |
201312 | 0.000 | 98.326 | 0.000 |
201403 | 0.000 | 99.695 | 0.000 |
201406 | 0.000 | 100.560 | 0.000 |
201409 | 0.000 | 100.428 | 0.000 |
201412 | 0.000 | 99.070 | 0.000 |
201503 | 0.000 | 99.621 | 0.000 |
201506 | 0.000 | 100.684 | 0.000 |
201509 | 0.000 | 100.392 | 0.000 |
201512 | 0.000 | 99.792 | 0.000 |
201603 | 0.000 | 100.470 | 0.000 |
201606 | 8.764 | 101.688 | 11.192 |
201609 | 7.414 | 101.861 | 9.452 |
201612 | 8.019 | 101.863 | 10.223 |
201703 | 9.614 | 102.862 | 12.137 |
201706 | 10.147 | 103.349 | 12.750 |
201709 | 7.529 | 104.136 | 9.389 |
201712 | 5.946 | 104.011 | 7.424 |
201803 | 6.665 | 105.290 | 8.220 |
201806 | 8.220 | 106.317 | 10.040 |
201809 | 6.378 | 106.507 | 7.776 |
201812 | 6.136 | 105.998 | 7.517 |
201903 | 7.257 | 107.251 | 8.787 |
201906 | 8.490 | 108.070 | 10.202 |
201909 | 7.342 | 108.329 | 8.801 |
201912 | 6.274 | 108.420 | 7.515 |
202003 | 4.908 | 108.902 | 5.853 |
202006 | 3.721 | 108.767 | 4.443 |
202009 | 0.799 | 109.815 | 0.945 |
202012 | 0.507 | 109.897 | 0.599 |
202103 | 0.753 | 111.754 | 0.875 |
202106 | 0.599 | 114.631 | 0.679 |
202109 | 0.357 | 115.734 | 0.401 |
202112 | -0.544 | 117.630 | -0.601 |
202203 | 0.540 | 121.301 | 0.578 |
202206 | 0.019 | 125.017 | 0.020 |
202209 | 0.703 | 125.227 | 0.729 |
202212 | 1.004 | 125.222 | 1.041 |
202303 | 0.665 | 127.348 | 0.678 |
202306 | 0.003 | 128.729 | 0.003 |
202309 | 0.001 | 129.860 | 0.001 |
Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.
Thank you for viewing the detailed overview of DMK Pharmaceuticals's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Dorbin John W. Jr. | officer: General Counsel | C/O ARCIMOTO, INC., 2034 WEST 2ND AVENUE, EUGENE OR 97402 |
Seth Cohen | officer: CFO | C/O NEWTEK BUSINESS SERVICES,INC, 1440 BROADWAY, NEW YORK NY 10018 |
Ebrahim Versi | director, officer: CEO | 11682 EL CAMINO REAL, STE 300, SAN DIEGO CA 92130 |
Jannine Versi | director | 11682 EL CAMINO REAL, STE 300, SAN DIEGO CA 92130 |
Vickie S Reed | director | TORREYPINES THERAPEUTICS, INC., 11085 NORTH TORREY PINES RD, STE 300, LA JOLLA CA 92037 |
David J. Marguglio | director | 2658 DEL MAR HEIGHTS RD., #555, DEL MAR CA 92014 |
Carlo Dennis J Phd | director, 10 percent owner, officer: President/CEO | PO BOX 1176, RANCHO SANTA FE CA 92067 |
Ronald B. Moss | officer: Chief Medical Officer | 11682 EL CAMINO REAL STE 300, SAN DIEGO CA 92130 |
David C. Benedicto | officer: Chief Financial Officer | 11682 EL CAMINO REAL, STE 300, SAN DIEGO CA 92130 |
Meera J. Desai | director | 1682 EL CAMINO REAL, STE 300, SAN DIEGO CA 92130 |
Robert O Hopkins | officer: Chief Financial Officer | 2658 DEL MAR HEIGHTS RD., #555, DEL MAR CA 92014 |
Karen K. Daniels | officer: Vice President of Operations | 11455 EL CAMINO REAL, SUITE 310, SAN DIEGO CA 92130 |
Howard C Birndorf | director | C/O NANOGEN INC, 10398 PACIFIC CENTER COURT, SAN DIEGO CA 92121 |
Roshawn A. Blunt | director | 11682 EL CAMINO REAL STE 300, SAN DIEGO CA 92130 |
Richard C Williams | director | 26001 OSPREY NEST COURT, BONITA SPRINGS FL 34134 |
From GuruFocus
By GuruFocus Research • 02-06-2024
By PRNewswire • 06-26-2023
By Marketwired • 06-26-2023
By Marketwired • 09-07-2023
By GuruFocus Research • 02-06-2024
By GuruFocus Research • 02-06-2024
By GuruFocus Research • 02-06-2024
By GuruFocus Research • 02-06-2024
By Marketwired • 08-04-2023
By GuruFocus Research • 02-06-2024